KEYS vs PPCB · P/E 57, rev $4.98B vs P/E 0.0, $3.9M cap
Keysight Technologies Inc (KEYS) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
PPCB does not have a complete income-statement cache yet.
KEYS currently screens at market cap $59.84B and trailing P/E 56.5. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the KEYS and PPCB stock pages for the full models.
Not investment advice.